

5th Human Cancer Immunology Course

Thursday October 10, 2019 **Institut Jules Bordet**

10:15-10:45 am REGISTRATION AND WELCOME COFFEE

10:45-11:00 am Welcome and Introduction

M. Piccart, MD PhD - A. Awada, MD PhD, Institut Jules Bordet - ULB,

Brussels (Belgium)

Immunological Memory

11:00-11:20 am Innate immune memory

Jorge Dominguez-Andrés, PhD, Radboud University Medical Center

(RadboudUMC), Nijmegen, The Netherlands (NL)

11:20-11:40 am Tissue resident memory T cells

Pleun Hombrink, PhD, Group Leader Sanquin Research, Amsterdam (NL)

11:40-12:00 am The relationship between immunological memory and clinical outcome

in cancer

Christian Ottensmeier, MD PhD, Professor of Experimental Cancer

Medecine, University of Southampton University, UK

Panel discussion 12:00-12:20 am

12:20-1:20 pm LUNCH

Non-malignant Elements of the Tumor Microenvironment

1:20-:2:00 pm New insights into the crosstalk between cells in the tumor

microenvironment

Agnès Noel, PhD, GIGA-Cancer - Université de Liège, Belgium

2:00-2:20 pm Intestinal microbiota and immune response interactions in human

cancers

Maria Paula Roberti, PhD, INSERM, Institut Gustave Roussy, Paris, France

2:20-2:40 pm Panel discussion

Accreditation





5th Human Cancer Immunology Course

Thursday October 10, 2019
Institut Jules Bordet

<u>Chronic Inflammation and Cancer:</u> An interplay between oncologists and immune disease specialists

2:40-3:00 pm	The link between thyroid autoimmunity and breast cancer Ilaria Muller, MD PhD, Cardiff University School of Medecine, UK Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan - Italy
3:00-3:20 pm	Chronic inflammation in transplantation and links with cancer Alain Lemoine, MD PhD, Transplant-Immunology, Erasme-IMI, Belgium
3:20-3:40 pm	Inflammation in chronic viral infections and links with cancer Massimo lavarone, MD PhD, Ospedale Maggiore Policlinico, University of Milan, Italy
3:40-4:10 pm	COFFEE BREAK
4:10-4:30 pm	Using viruses for immunotherapy in glioblastoma Magnus Essand, PhD, Uppsala University - Sweden
4:30-5:10 pm	Impact of vaccination on the development of cervical abnormalities and cancer Alejandra Castanon, MD, King's College London, UK
5:10-5:30 pm	Immunotherapy in HIV infected patients: what lessons can we learn for cancer treatment? Maria Gonzalez Cao, MD PhD, Institut Oncologico Dr Rosell, Dexeus University Hospital, Barcelona - Spain
5:30-5:50 pm	Panel discussion

Accreditation



Email: martine.piccart@bordet.be



5th Human Cancer Immunology Course

Friday October 11, 2019
Institut Jules Bordet

9:30-9:45 am

REGISTRATION AND WELCOME COFFEE

The use of corticosteroids during cancer treatment

9:45-10:00 am Negative effects on immune responses

Karen Willard-Gallo, PhD, Institut Jules Bordet, Belgium

10:00-10:15 am Positive attributes for controlling treatment toxicity

Sandrine Aspeslagh, MD PhD, UZ Brussel, Belgium

10:15-10:30 am **Discussion**

10-30-10:50 pm **COFFEE BREAK**

Predictive biomarkers and imaging of patients on immunotherapy

10:50-11:10 am Predictive biomarkers for immunotherapy: How far have we come (or

how much have we failed) in 2019?

Patrick Pauwels, MD PhD, Antwerp University Hospital, Belgium

11:10-11:30 am Scoring TIL in breast cancer: Ready for prime time use!

Hugo M. Horlings, MD PhD, Netherlands Cancer Institute, Amsterdam

(NL)

11:30-11:50 am iRECIST 1.1*

Jan Bogaerts, Scientific Director - EORTC Headquarters, Belgium

11:50-12:10 am In vivo imaging of immune responses by PET-CT: Murine models

Angela Krackhardt, MD, Technical University of Munich, Germany

12:10-12:30 am In vivo imaging of immune responses by PET-CT: Cancer patients

Antonia Dimitrakopoulou-Strauss, MD PhD, German Cancer Research

Center, Heidelberg, Germany

12:30-12:50 am Panel discussion

12:50-1:50 pm LUNCH Accreditation



5th Human Cancer Immunology Course

Friday October 11, 2019 **Institut Jules Bordet**

New developments in Immunotherapy: Pharma partner perspectives

1:50-2:05 pm Saeed Rafii, MD PhD FRCP, Senior Medical Director, Global

Development Oncology - Roche/Genentech, UK

2:05-2:20 pm Konstantinos Tryfonidis, MD PhD, Senior Principal Scientist, Clinical

Director, Oncology Clinical Research, Merck Research Laboratories, USA

Update on Immunotherapy in Human Cancer

2:20-2:40 pm **CAR T Cells in Clinical Trials: Achievements and challenges**

for hematological malignancies

Hinrich Abken, MD PhD, RCI Regensburg, Germany

Update on Immunotherapy in Solid Tumors

What is new in clinical practice using immunotherapy 2:40-3:00 pm

to treat solid tumors?

Ahmad Awada, MD PhD, Institut Jules Bordet, Belgium

Solid tumors with the best response rate and why?

3:00-3:20 pm The impact of active immunity on successful responses to

immunotherapy

Vibeke Kruse, MD PhD, Ghent University Hospital, Belgium

Solid tumors with a poor response rate and why?

Immunotherapy in pancreatic cancer: is there some light in 3:20-3:40 pm

this dark disease?

Christelle Bouchart, MD PhD Candidate, Institut Jules Bordet, Belgium

3:40-4:00 pm **Panel discussion**

CLOSING REMARKS 4:00-4:15 pm Accreditation

